Results 321 to 330 of about 55,676 (335)
Some of the next articles are maybe not open access.
Janus Activated Kinase inhibition in Myelofibrosis
Indian Journal of Cancer, 2012Janus Activated Kinase (JAK) 2 plays an important role in the pathogenesis of myelofibrosis (MF). Ruxolitinib (INCB018424, Jakafi) is a potent dual JAK1 and JAK2 inhibitor. In November 2011, it became approved by the US FDA for the treatment of intermediate or high-risk MF.
openaire +2 more sources
Thromboembolism and Janus Kinase Inhibitors
Drug Safety, 2020Fowzia Ibrahim, David L. Scott
openaire +3 more sources